Page 133 - 83_02

management of acute poisoning with or without liver Schaeffeler E, Nussler AK, et al. Interindividual
failure. Clin Toxicol (Phila) 2011;49:782-793. variability of canalicular ATP-binding-cassette
(ABC)-transporter expression in human liver.
54. Allen K, Jaeschke H, Copple BL. Bile acids induce Hepatology 2006;44:62-74.
inflammatory genes in hepatocytes: a novel 69. Kagawa T, Hirose S, Arase Y, Oka A, Anzai K,
mechanism of inflammation during obstructive Tsuruya K, et al. No contribution of the ABCB11
cholestasis. The American journal of pathology p.444A polymorphism in Japanese patients with drug-
2011;178:175-186. induced cholestasis. Drug Metab Dispos 2015;43:691-
697.
55. Cai SY, Ouyang X, Chen Y, Soroka CJ, Wang J, 70. Ulzurrun E, Stephens C, Crespo E, Ruiz-Cabello F,
Mennone A, et al. Bile acids initiate cholestatic liver Ruiz-Nunez J, Saenz-Lopez P, et al. Role of chemical
injury by triggering a hepatocyte-specific structures and the 1331T>C bile salt export pump
inflammatory response. JCI Insight 2017;2:e90780. polymorphism in idiosyncratic drug-induced liver
injury. Liver Int 2013;33:1378-1385.
56. Reuben A. Hy's law. Hepatology 2004;39:574-578. 71. Ho RH, Leake BF, Kilkenny DM, Meyer Zu
Schwabedissen HE, Glaeser H, Kroetz DL, et al.
57. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Polymorphic variants in the human bile salt export
Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver pump (BSEP; ABCB11): functional characterization
injury: an analysis of 461 incidences submitted to the and interindividual variability. Pharmacogenet
Spanish registry over a 10-year period. Genomics 2010;20:45-57.
Gastroenterology 2005;129:512-521. 72. Donato MT, Lopez-Riera M, Castell JV, Gomez-
Lechon MJ, Jover R. Both cholestatic and steatotic
58. Bjornsson ES, Jonasson JG. Drug-induced cholestasis. drugs trigger extensive alterations in the mRNA level
Clin Liver Dis 2013;17:191-209. of biliary transporters in rat hepatocytes: Application
to develop new predictive biomarkers for early drug
59. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, development. Toxicol Lett 2016;263:58-67.
Davern T, Serrano J, et al. Causes, clinical features, 73. Chiang JY. Bile acid metabolism and signaling. Compr
and outcomes from a prospective study of drug- Physiol 2013;3:1191-1212.
induced liver injury in the United States. 74. Ali AH, Carey EJ, Lindor KD. Recent advances in the
Gastroenterology 2008;135:1924-1934, 1934 e1921- development of farnesoid X receptor agonists. Ann
1924. Transl Med 2015;3:5.

60. Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, 293
Stephens C, Garcia-Cortes M, Garcia-Munoz B, et al.
Distinct phenotype of hepatotoxicity associated with
illicit use of anabolic androgenic steroids. Aliment
Pharmacol Ther 2015;41:116-125.

61. Perez MJ, Briz O. Bile-acid-induced cell injury and
protection. World J Gastroenterol 2009;15:1677-1689.

62. Roberts LR, Kurosawa H, Bronk SF, Fesmier PJ,
Agellon LB, Leung WY, et al. Cathepsin B
contributes to bile salt-induced apoptosis of rat
hepatocytes. Gastroenterology 1997;113:1714-1726.

63. Fickert P, Fuchsbichler A, Marschall HU, Wagner M,
Zollner G, Krause R, et al. Lithocholic acid feeding
induces segmental bile duct obstruction and
destructive cholangitis in mice. Am J Pathol
2006;168:410-422.

64. Halilbasic E, Claudel T, Trauner M. Bile acid
transporters and regulatory nuclear receptors in the
liver and beyond. J Hepatol 2013;58:155-168.

65. Sticova E, Jirsa M. New insights in bilirubin
metabolism and their clinical implications. World J
Gastroenterol 2013;19:6398-6407.

66. Zollner G, Trauner M. Nuclear receptors as therapeutic
targets in cholestatic liver diseases. Br J Pharmacol
2009;156:7-27.

67. Morgan RE, Trauner M, van Staden CJ, Lee PH,
Ramachandran B, Eschenberg M, et al. Interference
with bile salt export pump function is a susceptibility
factor for human liver injury in drug development.
Toxicol Sci 2010;118:485-500.

68. Meier Y, Pauli-Magnus C, Zanger UM, Klein K,

@Real Academia Nacional de Farmacia. Spain